Description: Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Home Page: www.luciddx.com
LUCD Technical Analysis
One Grand Central Place
New York,
NY
10165
United States
Phone:
212 949 4319
Officers
| Name | Title |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman & CEO |
| Mr. Dennis M. McGrath CPA | CFO, Pres & Sec. |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Cofounder & Strategic Advisor, Member of the Medical Advisor Board |
| Dr. Joseph Willis M.D. | Cofounder, Strategic Advisor & Member of Medical Advisory Board |
| Dr. Amitabh Chak M.D. | Cofounder, Strategic Advisor & Member of Medical Advisory Board |
| Mr. Shaun M. O'Neill M.B.A. | Exec. VP & COO |
| Richard D. Yazbeck | Chief Technology Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Mr. Adrian K. Miller | VP of Investor Relations |
| Dr. Brian J. deGuzman M.D. | Chief Compliance Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3721 |
| Price-to-Sales TTM: | 112.8254 |
| IPO Date: | 2021-10-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |